Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20595231 | 0.99 | BACE1 (0.53) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL22809583 | 0.89 | BACE1 (0.41) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL22809561 | 0.89 | BACE1 (0.41) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL22809481 | 0.82 | BACE1 (0.47) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL28350726 | 0.81 | BACE1 (0.47) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL2001524 | 0.74 | HPGD (0.48) | SCN9A | |
| SCHEMBL28354796 | 0.73 | SCN9A (0.48) | SCN9ASCN7AKCNH2KDM4ESCN5A | |
| SCHEMBL19732851 | 0.73 | NOS3 (0.50) | BACE1 | |
| SCHEMBL11351587 | 0.72 | BACE1 (0.51) | BACE1SCN9APDE1APDE1BPDE4B | |
| SCHEMBL4008713 | 0.71 | IDO1 (0.47) | KDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | BACE1 1350/4885SCN9A 9/4885PDE1A 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.